Stem definition | Drug id | CAS RN |
---|---|---|
antimycobacterials, diaminodiphenylsulfone derivatives | 782 | 80-08-0 |
Dose | Unit | Route |
---|---|---|
50 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 15 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 20.14 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 93 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.83 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.48 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.25 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 22 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 3, 1979 | FDA | JACOBUS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Methaemoglobinaemia | 540.28 | 15.64 | 112 | 7114 | 2050 | 46676786 |
Drug reaction with eosinophilia and systemic symptoms | 254.80 | 15.64 | 113 | 7113 | 29435 | 46649401 |
Haemolytic anaemia | 133.28 | 15.64 | 52 | 7174 | 9790 | 46669046 |
Blood methaemoglobin present | 51.02 | 15.64 | 9 | 7217 | 65 | 46678771 |
Type 2 lepra reaction | 42.22 | 15.64 | 7 | 7219 | 33 | 46678803 |
Off label use | 41.61 | 15.64 | 141 | 7085 | 379700 | 46299136 |
Treatment failure | 40.15 | 15.64 | 60 | 7166 | 93027 | 46585809 |
Skin odour abnormal | 39.41 | 15.64 | 13 | 7213 | 1506 | 46677330 |
Hidradenitis | 35.20 | 15.64 | 13 | 7213 | 2102 | 46676734 |
Hepatitis fulminant | 32.47 | 15.64 | 14 | 7212 | 3388 | 46675448 |
Idiopathic pneumonia syndrome | 31.53 | 15.64 | 8 | 7218 | 364 | 46678472 |
Type IIb hyperlipidaemia | 29.15 | 15.64 | 5 | 7221 | 30 | 46678806 |
Wound secretion | 27.59 | 15.64 | 13 | 7213 | 3867 | 46674969 |
Haemolysis | 27.54 | 15.64 | 15 | 7211 | 6044 | 46672792 |
Sepsis | 27.23 | 15.64 | 63 | 7163 | 135951 | 46542885 |
Pseudomonas infection | 25.68 | 15.64 | 17 | 7209 | 9741 | 46669095 |
Drug ineffective | 25.30 | 15.64 | 185 | 7041 | 677653 | 46001183 |
Myopathy | 24.66 | 15.64 | 16 | 7210 | 8865 | 46669971 |
Thyroid tuberculosis | 23.61 | 15.64 | 4 | 7222 | 22 | 46678814 |
Klebsiella infection | 23.56 | 15.64 | 14 | 7212 | 6648 | 46672188 |
Product use in unapproved indication | 22.86 | 15.64 | 46 | 7180 | 90227 | 46588609 |
Skin lesion | 22.37 | 15.64 | 24 | 7202 | 26689 | 46652147 |
Eosinophilic myocarditis | 21.92 | 15.64 | 6 | 7220 | 367 | 46678469 |
Skin hyperpigmentation | 21.06 | 15.64 | 12 | 7214 | 5270 | 46673566 |
Pyrexia | 20.38 | 15.64 | 107 | 7119 | 348695 | 46330141 |
Cyanosis | 20.23 | 15.64 | 18 | 7208 | 15953 | 46662883 |
Dermatitis herpetiformis | 20.03 | 15.64 | 3 | 7223 | 6 | 46678830 |
Leukopenia | 19.96 | 15.64 | 37 | 7189 | 68306 | 46610530 |
Drug-induced liver injury | 19.86 | 15.64 | 22 | 7204 | 25346 | 46653490 |
Marrow hyperplasia | 19.60 | 15.64 | 6 | 7220 | 546 | 46678290 |
Oxygen saturation decreased | 18.41 | 15.64 | 36 | 7190 | 69128 | 46609708 |
Angioedema | 17.86 | 15.64 | 26 | 7200 | 39316 | 46639520 |
Bronchopulmonary aspergillosis | 17.20 | 15.64 | 12 | 7214 | 7484 | 46671352 |
Choriomeningitis lymphocytic | 16.96 | 15.64 | 3 | 7223 | 22 | 46678814 |
Acne | 16.86 | 15.64 | 18 | 7208 | 19901 | 46658935 |
Skin exfoliation | 16.77 | 15.64 | 23 | 7203 | 32915 | 46645921 |
Rash | 16.00 | 15.64 | 102 | 7124 | 356410 | 46322426 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Methaemoglobinaemia | 205.49 | 16.02 | 58 | 7416 | 2452 | 29942552 |
Type 2 lepra reaction | 165.55 | 16.02 | 34 | 7440 | 353 | 29944651 |
Drug reaction with eosinophilia and systemic symptoms | 161.53 | 16.02 | 96 | 7378 | 28392 | 29916612 |
Haemolytic anaemia | 99.49 | 16.02 | 49 | 7425 | 9961 | 29935043 |
Vanishing bile duct syndrome | 85.62 | 16.02 | 22 | 7452 | 646 | 29944358 |
Type 1 lepra reaction | 55.46 | 16.02 | 9 | 7465 | 19 | 29944985 |
Brain abscess | 52.07 | 16.02 | 21 | 7453 | 2660 | 29942344 |
Mycobacterium avium complex infection | 48.43 | 16.02 | 20 | 7454 | 2691 | 29942313 |
Pleocytosis | 48.28 | 16.02 | 13 | 7461 | 459 | 29944545 |
Lepromatous leprosy | 44.67 | 16.02 | 9 | 7465 | 84 | 29944920 |
Pyrexia | 42.52 | 16.02 | 165 | 7309 | 294324 | 29650680 |
Nocardiosis | 37.58 | 16.02 | 18 | 7456 | 3437 | 29941567 |
HIV associated nephropathy | 35.09 | 16.02 | 9 | 7465 | 262 | 29944742 |
Blood methaemoglobin present | 33.74 | 16.02 | 6 | 7468 | 26 | 29944978 |
Haemolysis | 32.37 | 16.02 | 21 | 7453 | 7210 | 29937794 |
Drug-induced liver injury | 30.84 | 16.02 | 32 | 7442 | 21242 | 29923762 |
Toxoplasmosis | 30.45 | 16.02 | 11 | 7463 | 1032 | 29943972 |
Pancytopenia | 29.11 | 16.02 | 65 | 7409 | 84987 | 29860017 |
Papillary cystadenoma lymphomatosum | 25.97 | 16.02 | 5 | 7469 | 36 | 29944968 |
Mucormycosis | 25.32 | 16.02 | 16 | 7458 | 5252 | 29939752 |
Leprosy | 25.27 | 16.02 | 6 | 7468 | 126 | 29944878 |
Aeromonas infection | 25.15 | 16.02 | 7 | 7467 | 280 | 29944724 |
Induration | 24.89 | 16.02 | 9 | 7465 | 847 | 29944157 |
Thrombotic microangiopathy | 24.58 | 16.02 | 19 | 7455 | 8591 | 29936413 |
Disseminated cryptococcosis | 23.45 | 16.02 | 9 | 7465 | 1000 | 29944004 |
Pneumonia cryptococcal | 22.49 | 16.02 | 8 | 7466 | 718 | 29944286 |
Photophobia | 21.45 | 16.02 | 15 | 7459 | 5821 | 29939183 |
Cushingoid | 21.25 | 16.02 | 11 | 7463 | 2476 | 29942528 |
Pemphigoid | 20.17 | 16.02 | 16 | 7458 | 7512 | 29937492 |
Epstein-Barr virus infection | 19.58 | 16.02 | 15 | 7459 | 6691 | 29938313 |
Death | 18.92 | 16.02 | 38 | 7436 | 357245 | 29587759 |
Fluid imbalance | 18.86 | 16.02 | 6 | 7468 | 382 | 29944622 |
Granuloma | 18.79 | 16.02 | 10 | 7464 | 2382 | 29942622 |
Tuberculoid leprosy | 18.57 | 16.02 | 4 | 7470 | 53 | 29944951 |
Graft versus host disease | 17.91 | 16.02 | 17 | 7457 | 10133 | 29934871 |
Neuritis | 16.99 | 16.02 | 6 | 7468 | 527 | 29944477 |
Thrombocytopenia | 16.66 | 16.02 | 73 | 7401 | 136971 | 29808033 |
Source | Code | Description |
---|---|---|
ATC | D10AX05 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Other anti-acne preparations for topical use |
ATC | J04BA02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF LEPRA Drugs for treatment of lepra |
FDA CS | M0020791 | Sulfones |
CHEBI has role | CHEBI:35441 | anti-infective drugs |
CHEBI has role | CHEBI:35472 | anti-inflammatory drugs |
CHEBI has role | CHEBI:35816 | leprostatic |
CHEBI has role | CHEBI:38068 | antimalarials |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000962 | Antimalarials |
MeSH PA | D000977 | Antiparasitic Agents |
MeSH PA | D000981 | Antiprotozoal Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D005493 | Folic Acid Antagonists |
MeSH PA | D007917 | Leprostatic Agents |
FDA EPC | N0000175881 | Sulfone |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Leprosy | indication | 81004002 | DOID:1024 |
Acne vulgaris | indication | 88616000 | |
Dermatitis herpetiformis | indication | 111196000 | DOID:8505 |
Subcorneal pustular dermatosis | off-label use | 25147002 | DOID:8508 |
Benign mucous membrane pemphigoid | off-label use | 34250006 | DOID:11656 |
Systemic lupus erythematosus | off-label use | 55464009 | DOID:9074 |
Granuloma annulare | off-label use | 65508009 | DOID:3777 |
Pyoderma gangrenosum | off-label use | 74578003 | DOID:8553 |
Pemphigoid | off-label use | 86142006 | |
Actinomycotic mycetoma | off-label use | 187089001 | |
Toxoplasmosis | off-label use | 187192000 | DOID:9965 |
Pneumocystosis jiroveci pneumonia | off-label use | 415125002 | DOID:11339 |
Pneumocystis Carinii Pneumonia Prevention | off-label use | ||
Anemia due to enzyme deficiency | contraindication | 111577008 | |
Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
Deficiency of cytochrome-b>5< reductase | contraindication | 124184009 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.34 | Basic |
pKa2 | 1.73 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
7.5% | ACZONE | ALMIRALL | N207154 | Feb. 24, 2016 | RX | GEL | TOPICAL | Sept. 10, 2022 | NEW PATIENT POPULATION |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.74 | CHEMBL | |||||
Cytochrome P450 3A4 | Enzyme | Ki | 4.57 | WOMBAT-PK | |||||
Glucose-6-phosphate 1-dehydrogenase | Enzyme | WOMBAT-PK | |||||||
Dihydropteroate synthase 1 | Enzyme | INHIBITOR | IC50 | 5.90 | WOMBAT-PK | CHEMBL | |||
Dihydrofolate reductase | Enzyme | IC50 | 5.82 | CHEMBL | |||||
Dihydropteroate synthetase, putative | Unclassified | IC50 | 4.91 | CHEMBL |
ID | Source |
---|---|
4019264 | VUID |
N0000147467 | NUI |
D00592 | KEGG_DRUG |
4019264 | VANDF |
C0010980 | UMLSCUI |
CHEBI:4325 | CHEBI |
CHEMBL1043 | ChEMBL_ID |
DB00250 | DRUGBANK_ID |
D003622 | MESH_DESCRIPTOR_UI |
2955 | PUBCHEM_CID |
10934 | IUPHAR_LIGAND_ID |
1676 | INN_ID |
8W5C518302 | UNII |
3108 | RXNORM |
4536 | MMSL |
682 | MMSL |
d00098 | MMSL |
003003 | NDDF |
17308007 | SNOMEDCT_US |
387096002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
ACZONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-3670 | GEL | 50 mg | TOPICAL | NDA | 26 sections |
ACZONE7.5 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5206 | GEL | 75 mg | TOPICAL | NDA | 25 sections |
DAPSONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7018 | TABLET | 100 mg | ORAL | ANDA | 11 sections |
DAPSONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7019 | TABLET | 25 mg | ORAL | ANDA | 11 sections |
DAPSONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-654 | TABLET | 25 mg | ORAL | ANDA | 19 sections |
DAPSONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-655 | TABLET | 100 mg | ORAL | ANDA | 19 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13925-504 | TABLET | 25 mg | ORAL | ANDA | 19 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13925-505 | TABLET | 100 mg | ORAL | ANDA | 19 sections |
Aczone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16110-526 | GEL | 75 mg | TOPICAL | NDA | 26 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-956 | GEL | 50 mg | TOPICAL | ANDA | 26 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29033-036 | TABLET | 25 mg | ORAL | ANDA | 18 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29033-037 | TABLET | 100 mg | ORAL | ANDA | 18 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-298 | TABLET | 25 mg | ORAL | ANDA | 21 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-299 | TABLET | 100 mg | ORAL | ANDA | 21 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-222 | TABLET | 25 mg | ORAL | ANDA | 21 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-223 | TABLET | 100 mg | ORAL | ANDA | 21 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47781-333 | TABLET | 25 mg | ORAL | ANDA | 19 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47781-334 | TABLET | 100 mg | ORAL | ANDA | 19 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49938-101 | TABLET | 100 mg | ORAL | ANDA | 18 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49938-101 | TABLET | 100 mg | ORAL | ANDA | 18 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49938-102 | TABLET | 25 mg | ORAL | ANDA | 18 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49938-102 | TABLET | 25 mg | ORAL | ANDA | 18 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1387 | GEL | 50 mg | TOPICAL | ANDA | 26 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1388 | GEL | 75 mg | TOPICAL | ANDA | 27 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-4197 | TABLET | 25 mg | ORAL | ANDA | 20 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-4198 | TABLET | 100 mg | ORAL | ANDA | 20 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-5307 | GEL | 75 mg | TOPICAL | NDA authorized generic | 26 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-2817 | TABLET | 25 mg | ORAL | ANDA | 18 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3801 | TABLET | 100 mg | ORAL | ANDA | 18 sections |
Dapsone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55695-005 | TABLET | 25 mg | ORAL | ANDA | 18 sections |